Limits...
Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.

Vedel-Krogh S, Nielsen SF, Nordestgaard BG - PLoS ONE (2015)

Bottom Line: Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years.Results were robust in all sensitivity analyses.Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Herlev and Gentofte Hospitals, Copenhagen University Hospital, Herlev, Denmark.

ABSTRACT

Introduction: We hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality.

Methods: We studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study.

Results: The cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786 + 3,572) and idiopathic lung fibrosis (n = 261 + 522) was higher for statin users versus never users (log-rank: P = 7 · 10(-9) and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses.

Conclusion: Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

No MeSH data available.


Related in: MedlinePlus

Risk of all-cause and cause-specific mortality in statin users versus never users.Hazard ratios are shown after multivariable adjustment, after additional adjustment for propensity score, and after multivariable adjustment with the use of Fine and Gray subhazard regression allowing for competing risk of death.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608706&req=5

pone.0140571.g004: Risk of all-cause and cause-specific mortality in statin users versus never users.Hazard ratios are shown after multivariable adjustment, after additional adjustment for propensity score, and after multivariable adjustment with the use of Fine and Gray subhazard regression allowing for competing risk of death.

Mentions: After multivariable adjustment, the hazard ratio for mortality for statin users versus never users from respiratory disease was 0.61 (95% CI, 0.52 to 0.73), for mortality from cardiovascular disease 1.05 (0.89–1.22), and for mortality from other causes 0.68 (0.60–0.76) (Fig 4). Among patients diagnosed with idiopathic lung fibrosis, the statistical power was too low to estimate reliable hazard ratios for cause-specific mortality.


Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.

Vedel-Krogh S, Nielsen SF, Nordestgaard BG - PLoS ONE (2015)

Risk of all-cause and cause-specific mortality in statin users versus never users.Hazard ratios are shown after multivariable adjustment, after additional adjustment for propensity score, and after multivariable adjustment with the use of Fine and Gray subhazard regression allowing for competing risk of death.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608706&req=5

pone.0140571.g004: Risk of all-cause and cause-specific mortality in statin users versus never users.Hazard ratios are shown after multivariable adjustment, after additional adjustment for propensity score, and after multivariable adjustment with the use of Fine and Gray subhazard regression allowing for competing risk of death.
Mentions: After multivariable adjustment, the hazard ratio for mortality for statin users versus never users from respiratory disease was 0.61 (95% CI, 0.52 to 0.73), for mortality from cardiovascular disease 1.05 (0.89–1.22), and for mortality from other causes 0.68 (0.60–0.76) (Fig 4). Among patients diagnosed with idiopathic lung fibrosis, the statistical power was too low to estimate reliable hazard ratios for cause-specific mortality.

Bottom Line: Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years.Results were robust in all sensitivity analyses.Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Biochemistry, Herlev and Gentofte Hospitals, Copenhagen University Hospital, Herlev, Denmark.

ABSTRACT

Introduction: We hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality.

Methods: We studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study.

Results: The cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786 + 3,572) and idiopathic lung fibrosis (n = 261 + 522) was higher for statin users versus never users (log-rank: P = 7 · 10(-9) and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses.

Conclusion: Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality.

No MeSH data available.


Related in: MedlinePlus